Title: Randomized controlled trial of KW-6356 monotherapy in patients with early untreated Parkinson's disease.
PMID: 37948832

Abstract:
KW-6356 is a novel selective adenosine A<sub>2A</sub> receptor antagonist/inverse agonist. We evaluated the efficacy and safety of KW-6356 as monotherapy in patients with early, untreated Parkinson's disease (PD).